RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of up to $30 million. In addition, NephroGenex expects to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its common stock in connection with the offering. All of the shares in the offering will be sold by NephroGenex.
Help employers find you! Check out all the jobs and post your resume.
